Oculis (NASDAQ:OCS) Reaches New 52-Week Low – Should You Sell?

Oculis Holding AG (NASDAQ:OCS)’s share price hit a new 52-week low during trading on Friday . The company traded as low as $11.29 and last traded at $11.3170, with a volume of 284111 shares traded. The stock had previously closed at $11.83.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the company. Stifel Nicolaus reduced their target price on Oculis from $50.00 to $40.00 and set a “buy” rating on the stock in a research note on Monday. Wall Street Zen lowered Oculis from a “hold” rating to a “sell” rating in a research report on Saturday, March 7th. JPMorgan Chase & Co. dropped their price target on Oculis from $42.00 to $23.00 and set an “overweight” rating on the stock in a research report on Wednesday. Robert W. Baird dropped their price target on Oculis from $49.00 to $38.00 and set an “outperform” rating on the stock in a research report on Monday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Oculis in a research report on Tuesday, April 21st. Nine equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $38.33.

Oculis Stock Down 5.4%

The firm has a market capitalization of $649.09 million, a P/E ratio of -5.26 and a beta of 0.23. The company has a quick ratio of 5.18, a current ratio of 5.18 and a debt-to-equity ratio of 0.01. The company has a fifty day simple moving average of $26.72 and a 200 day simple moving average of $25.03.

Oculis (NASDAQ:OCS) last announced its quarterly earnings results on Friday, May 8th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.14). The business had revenue of $0.26 million for the quarter, compared to the consensus estimate of $0.25 million. Oculis had a negative net margin of 8,460.67% and a negative return on equity of 56.78%. On average, equities analysts expect that Oculis Holding AG will post -2.23 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of OCS. Geode Capital Management LLC lifted its holdings in Oculis by 27.7% in the second quarter. Geode Capital Management LLC now owns 29,436 shares of the company’s stock valued at $571,000 after acquiring an additional 6,384 shares during the period. Marshall Wace LLP purchased a new stake in Oculis in the second quarter worth about $393,000. Bank of America Corp DE increased its position in Oculis by 2.2% in the second quarter. Bank of America Corp DE now owns 40,512 shares of the company’s stock worth $786,000 after buying an additional 878 shares in the last quarter. Woodline Partners LP increased its position in Oculis by 65.8% in the third quarter. Woodline Partners LP now owns 83,833 shares of the company’s stock worth $1,474,000 after buying an additional 33,265 shares in the last quarter. Finally, Aventura Private Wealth LLC purchased a new stake in Oculis in the fourth quarter worth about $80,000. Institutional investors own 22.30% of the company’s stock.

Oculis Company Profile

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.